July 31, 2018 — Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: MRRBF) is pleased to announce the signing of a research and development Industry Service Agreement (“ISA”) with the British Columbia Institute of Technology (BCIT).
The research and development ISA is a collaboration between Viridium and its wholly-owned subsidiary Experion Biotechnologies Inc. (“Experion”), a licensed producer under the ACMPR) and BCIT’s Natural Health & Food Products Research Group which hold a controlled substance dealer’s License. Under the terms of the agreement BCIT will supply specific phenotypic medical cannabis chemovars to Experion for cultivation and harvesting in support of BCIT’s research program. Experion will have exclusive rights to the genetic outcomes of BCIT’s work to be commercialized for the medical and recreational markets. BCIT and Experion will share the benefits of these commercialization efforts as royalty agreement.
Mr. Jarrett Malnarick, CEO commented, “Diversity and scientific knowledge of your genetics are key for any License Producer to succeed in the cannabis industry. Not only does this agreement open up a new channel for genetics development, but also enhances Experion’s expertise concerning cannabis strains and their respective applications and potential.”
Viridium Pacific Group Ltd. is a biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production (Experion Biotechnologies), property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.). Experion Biotechnologies Inc. is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.
More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.